bivalent pfizer bnt vaccine (Pfizer Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Pfizer Inc bivalent pfizer bnt vaccine
Bivalent Pfizer Bnt Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-bnt/bivalent+bnt+pfizer+vaccine/pmc12390948__mmc5-912-44-45
Average 86 stars, based on 1 article reviews

bivalent pfizer bnt vaccine - by Bioz Stars, 2026-09

86/100 stars

Images

In Vitro:

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: Although our results are the first to report protection in a real-life setting, they are in line with in vitro studies; Argentinian researchers found that a heterologous booster with ChAdOx1, Sputnik V, or Pfizer-BNT vaccines markedly increased the neutralising activity against the omicron variant and was maintained up to 90 days in elderly people with primary schemes of Sinopharm.

Article Title: On the occassion of world kidney day 2023; renal impacts of COVID-19
Article Snippet: This study showed cases who injected Pfizer-BNT and developed AKI had the highest mortality (19.78%) compared to those who received Moderna (17.78%), or Janssen (12.36%).

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In December 2020, Argentina started the vaccination campaign against COVID-19 with Sputnik V and progressively incorporated ChAdOx1, Sinopharm, CanSino, Pfizer-BNT, Moderna vaccines, and combinations of Sputnik V component 1/Moderna, Sputnik V/ChAdOx1, and Sputnik V/CanSino, among others, in settings of limited vaccine availability., Vaccination rollout developed according to recommendations from the National Ministry of Health, prioritising individuals with higher risk of COVID-19.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In Chile, after a Sinovac primary scheme, heterologous boosting with ChAdOx1 or Pfizer-BNT was associated with higher VE than homologous boosting against symptomatic infection (90% for ChAdOx1; 93% for Pfizer-BNT; and 68% for Sinovac), COVID-associated hospitalisations (96%, 89%, and 75%, respectively), and intensive care unit admission (98%, 90%, and 79%, respectively), during the period of delta VOC predominance.

Article Title: Skin Cancer in Solid Organ Transplant Recipients: A Review for the Nondermatologist.
Article Snippet: Dr. Poland provides consultative advice to AiZtech; AstraZeneca UK Limited; Eli Lilly and Company; Emergent Biosolutions; Exelixis, Inc.; Genevant Sciences, Inc.; GlaxoSmithKline; Janssen Global Services, LLC; Medicago USA; Merck & Co. Inc.; Moderna; Novavax; Pfizer-BNT; Regeneron Pharmaceuticals, Inc.; Sanofi; Syneos Health; and Vyriad.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: The first studies reporting heterologous boosters in real life originated in the United Kingdom during the pre-omicron period, where Pfizer-BNT administered after a primary scheme of ChAdOx1 had 93% VE against symptomatic disease, compared to the unvaccinated.

Vaccines:

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In December 2020, Argentina started the vaccination campaign against COVID-19 with Sputnik V and progressively incorporated ChAdOx1, Sinopharm, CanSino, Pfizer-BNT, Moderna vaccines, and combinations of Sputnik V component 1/Moderna, Sputnik V/ChAdOx1, and Sputnik V/CanSino, among others, in settings of limited vaccine availability., Vaccination rollout developed according to recommendations from the National Ministry of Health, prioritising individuals with higher risk of COVID-19.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In Chile, after a Sinovac primary scheme, heterologous boosting with ChAdOx1 or Pfizer-BNT was associated with higher VE than homologous boosting against symptomatic infection (90% for ChAdOx1; 93% for Pfizer-BNT; and 68% for Sinovac), COVID-associated hospitalisations (96%, 89%, and 75%, respectively), and intensive care unit admission (98%, 90%, and 79%, respectively), during the period of delta VOC predominance.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: The first studies reporting heterologous boosters in real life originated in the United Kingdom during the pre-omicron period, where Pfizer-BNT administered after a primary scheme of ChAdOx1 had 93% VE against symptomatic disease, compared to the unvaccinated.

Activity Assay:

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In December 2020, Argentina started the vaccination campaign against COVID-19 with Sputnik V and progressively incorporated ChAdOx1, Sinopharm, CanSino, Pfizer-BNT, Moderna vaccines, and combinations of Sputnik V component 1/Moderna, Sputnik V/ChAdOx1, and Sputnik V/CanSino, among others, in settings of limited vaccine availability., Vaccination rollout developed according to recommendations from the National Ministry of Health, prioritising individuals with higher risk of COVID-19.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In Chile, after a Sinovac primary scheme, heterologous boosting with ChAdOx1 or Pfizer-BNT was associated with higher VE than homologous boosting against symptomatic infection (90% for ChAdOx1; 93% for Pfizer-BNT; and 68% for Sinovac), COVID-associated hospitalisations (96%, 89%, and 75%, respectively), and intensive care unit admission (98%, 90%, and 79%, respectively), during the period of delta VOC predominance.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: The first studies reporting heterologous boosters in real life originated in the United Kingdom during the pre-omicron period, where Pfizer-BNT administered after a primary scheme of ChAdOx1 had 93% VE against symptomatic disease, compared to the unvaccinated.

Variant Assay:

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In December 2020, Argentina started the vaccination campaign against COVID-19 with Sputnik V and progressively incorporated ChAdOx1, Sinopharm, CanSino, Pfizer-BNT, Moderna vaccines, and combinations of Sputnik V component 1/Moderna, Sputnik V/ChAdOx1, and Sputnik V/CanSino, among others, in settings of limited vaccine availability., Vaccination rollout developed according to recommendations from the National Ministry of Health, prioritising individuals with higher risk of COVID-19.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In Chile, after a Sinovac primary scheme, heterologous boosting with ChAdOx1 or Pfizer-BNT was associated with higher VE than homologous boosting against symptomatic infection (90% for ChAdOx1; 93% for Pfizer-BNT; and 68% for Sinovac), COVID-associated hospitalisations (96%, 89%, and 75%, respectively), and intensive care unit admission (98%, 90%, and 79%, respectively), during the period of delta VOC predominance.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: The first studies reporting heterologous boosters in real life originated in the United Kingdom during the pre-omicron period, where Pfizer-BNT administered after a primary scheme of ChAdOx1 had 93% VE against symptomatic disease, compared to the unvaccinated.

Virus:

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In December 2020, Argentina started the vaccination campaign against COVID-19 with Sputnik V and progressively incorporated ChAdOx1, Sinopharm, CanSino, Pfizer-BNT, Moderna vaccines, and combinations of Sputnik V component 1/Moderna, Sputnik V/ChAdOx1, and Sputnik V/CanSino, among others, in settings of limited vaccine availability., Vaccination rollout developed according to recommendations from the National Ministry of Health, prioritising individuals with higher risk of COVID-19.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: In Chile, after a Sinovac primary scheme, heterologous boosting with ChAdOx1 or Pfizer-BNT was associated with higher VE than homologous boosting against symptomatic infection (90% for ChAdOx1; 93% for Pfizer-BNT; and 68% for Sinovac), COVID-associated hospitalisations (96%, 89%, and 75%, respectively), and intensive care unit admission (98%, 90%, and 79%, respectively), during the period of delta VOC predominance.

Article Title: Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Article Snippet: The first studies reporting heterologous boosters in real life originated in the United Kingdom during the pre-omicron period, where Pfizer-BNT administered after a primary scheme of ChAdOx1 had 93% VE against symptomatic disease, compared to the unvaccinated.

Review